The speakers below have been approved for Continuing Education Credits. To redeem your credits, locate the presentation you watched and click on the CE buttons for further direction. For more general information regarding continuing education, the processes to receive credits, and the accreditation bodies, Click here
Labroots and the Drug Discovery planning committee are pleased to announce the 5th Annual Drug Discovery & Development Virtual Conference. Labroots will host this online-only event on February 23, 2022. The Drug Discovery planning committee will invite speakers from industry and academia to discuss key challenges, new opportunities, and recent successes in the current landscape of drug discovery and development.
Call for Posters — Virtual poster sessions offer the opportunity to present data to a global audience via a PDF poster and video summary, and discuss results with interested colleagues through email. Plan now to have your poster included in the 2022 Drug Discovery & Development Virtual Event. Submission is free. Submit your abstract here.
Our virtual conference allows you to participate in a global setting with no travel or cost to you. The event will remain open for 2 years from the date of the live event, and the webinars will be available for unlimited on-demand viewing. This virtual conference also offers increased reach for the global drug discovery community with a high degree of interaction through live-streaming video and chat sessions.
Labroots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this event, you can earn 1 Continuing Education credit per presentation for a maximum of 30 credits.
Use #LRdrug to follow the conversation!
ATCC is the premier global biological materials resource and standards organization whose mission focuses on the acquisition, authentication, production, preservation, development, and distribution of standard reference microorganisms, cell lines, and other materials. While ...See more See less
Sino Biological, Inc. is a global leader in manufacturing affordable, high-quality reagents, including recombinant proteins, antibodies and cDNA clones-all in-house. We provide a one-stop shop for researchers and pharmaceutical companies around the world, helping our customers ...See more See less
NanoString Technologies (NASDAQ: NSTG) is a publicly held provider of life science tools for translational research and molecular diagnostics. The company's technology enables a wide variety of basic research, translational medicine and in vitro diagnostics applications ...See more See less
The Sartorius Group is a leading international partner of biopharmaceutical research and the industry. With innovative laboratory instruments and consumables, the Group's Lab Products & Services Division concentrates on serving the needs of laboratories performing research and ...See more See less
For over 30 years, Miltenyi Biotec has been a leader in the development of products that empower the advancement of biomedical research and enable cell and gene therapy. We provide innovative tools to help with your sample preparation, cell isolation, cell culture, and cell ...See more See less
Our purpose is to solve the toughest problems in life science by collaborating with the global scientific community - and through that, we aim to accelerate access to better health for people everywhere.
At Luminex, our mission is to empower labs to obtain reliable, timely, and actionable answers, ultimately advancing health. We offer a wide range of solutions applicable in diverse markets including clinical diagnostics, pharmaceutical drug discovery, biomedical research, genomic ...See more See less
QIAGEN N.V., a Netherlands holding company, is the leading global provider of Sample & Assay Technologies that are used to transform biological materials into valuable molecular information. Sample technologies are used to isolate and process DNA, RNA and proteins from biological ...See more See less
Despite incredible therapeutic innovations, the process for manufacturing these life-changing drugs lagged behind. Because of the largely paper-based processes involved in pharma manufacturing, millions of dollars were lost in drug batches due to quality deviations. These ...See more See less
Matt entered the research field over 20 years ago as a lab animal technician at the TSI/Mason contract research facility. He has worked at both contract facilities such as TSI and OREAD Biosafety as well in industry at Pharmacia, Pfizer, and Sanofi-Aventis. During that period he ...See more See less
An Associate Professor with Midwestern University, Dr. Annette Gilchrist has a PhD in Immunology from the University of Connecticut Health Center and a MS in Biochemistry from the University of Connecticut. Previously, she was with Cue Biotech and Caden Biosciences, companies she ...See more See less
Professor Pfleger is Director, Biomedical Innovation at The University of Western Australia (UWA) and the MTPConnect Western Australian Life Sciences Innovation Hub. He is also Head of Molecular Endocrinology and Pharmacology at the UWA Centre for Medical Research and Harry ...See more See less
Between 1994-2015 he worked at EKF Diagnostics in Wales (formerly Argutus Medical) where he introduced and promoted a wide range of novel kidney and liver tests, including important biomarkers that are now being evaluated by the IMI (Innovative Medicines Initiative) and FDA as ...See more See less
Over the past 16 years, Mr. Shipton has amassed deep domain expertise in cell-based products and services. Currently serving as President of Novabiosis, Inc. Mr. Shipton brings a skill for implementing sales-driven business strategies, an extensive track record of meeting and ...See more See less